Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsallcareadvantage DPP-4 inhibitors Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 024.2

    Dipeptidyl peptidase-4 (DPP-4) inhibitors prior authorization

    Customize your policy alerts

    Sign up for allcareadvantage Policy 024.2 alerts

    Get alerted when Policy 024.2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization coverage rules for non-preferred and non-formulary dipeptidyl peptidase-4 (DPP-4) inhibitors for members with type 2 diabetes mellitus, including combination agents containing metformin and DPP-4 inhibitors.

    Policy Summary
    Payerallcareadvantage
    PolicyDipeptidyl peptidase-4 (DPP-4) inhibitors prior authorization
    Policy CodePolicy 024.2
    Change TypeNo material change
    Effective DateMar 28, 2025
    Last ReviewMar 28, 2027
    Next Review DateMar 28, 2027
    Key ActionObtain prior authorization and document diagnosis plus trials/failures or contraindications to metformin and preferred DPP-4 agents; approvals granted up to 1 year when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Type 2 diabetesIndication
    Up to 1 yearApproval length
    Class SpecificClassification
    7Agents listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Authorization

    Covered when ALL of the following are met

    Initial Authorization: 1) Documentation supports a diagnosis of type 2 diabetes mellitus; 2) Member has tried and failed, or has a contraindication to, first-line treatment with metformin; 3) For non-preferred formulary agents: member has tried/failed or has a contraindication to a preferred formulary DPP-4 inhibitor OR provider submits a clinical rationale supporting use of the non-preferred agent over the preferred agent; 4) For non-formulary agents: member has tried/failed or has a contraindication to both a preferred formulary agent and a non-preferred formulary agent OR provider submits a clinical rationale supporting use of the non-formulary agent over all formulary agents.

    Approval length up to 1 year; preserve branch logic for preferred vs non-preferred vs non-formulary.

    Renewal Authorization

    Covered when ALL of the following are met

    Renewal Authorization: 1) Member met prior authorization criteria for the initial authorization; 2) Recent chart notes support continuation of the medication.

    Approve up to 1 year when criteria are met; otherwise deny.

    Coverage for dipeptidyl peptidase‑4 (DPP‑4) inhibitors is limited to members with a documented diagnosis of type 2 diabetes mellitus. If documentation does not support a diagnosis of type 2 diabetes mellitus, the request must be denied.

    Initial Therapy Requirements

    Initial therapy criteria

    Initial therapy requirements

    Initial therapy: 1) Diagnosis of type 2 diabetes mellitus; AND 2) Trial and failure of, or documented contraindication to, first-line metformin; AND 3) For non-preferred formulary DPP-4 agents: trial/failure or contraindication to a preferred formulary DPP-4 inhibitor is required unless a clinical rationale is provided by the provider; AND 4) For non-formulary agents: trial/failure or contraindication to both preferred and non-preferred formulary agents is required unless a clinical rationale is provided by the provider.

    Approval up to 1 year.

    Renewal / Continuation Criteria

    Renewal criteria

    Renewal requires:

    Renewal: 1) Member met the PA criteria for initial authorization; AND 2) Recent chart notes support continued clinical benefit and need for the medication.

    Approve up to 1 year when met; otherwise deny.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required; approvals up to 1 year

    Prior authorization is required for non-preferred and non-formulary DPP-4 (DPP‑IV) inhibitors. When all coverage criteria are met, approvals are granted for up to 1 year.

    Step Therapy

    Step requirement: metformin (and preferred agents as applicable)

    Members must have tried and failed, or have a documented contraindication to, first-line treatment with metformin before non-preferred formulary DPP-4 agents are approved. Additionally, failure/contraindication to a preferred formulary DPP-4 inhibitor is required before approving non-formulary agents (unless a clinical rationale is submitted).

    Documentation Required

    Step Therapy Requirements

    StepRequired prior therapy / conditionNext authorized agentCoverage status
    {"text":"1","status":""}|{"text":"Documentation supports diagnosis of type 2 diabetes mellitus","status":""}|{"text":"Proceed to trial of metformin","status":""}|{"text":"","status":""}
    {"text":"2","status":""}|{"text":"Trial and failure of, or contraindication to, first‑line metformin","status":""}|{"text":"Trial of preferred formulary DPP‑4 inhibitor (or approval if contraindication)","status":""}|{"text":"","status":""}
    {"text":"3","status":""}|{"text":"Trial and failure of, or contraindication to, preferred formulary DPP‑4 inhibitor OR provider submits clinical rationale supporting non‑preferred agent over preferred","status":""}|{"text":"Non‑preferred formulary DPP‑4 agent — approve up to 1 year when criteria met","status":"covered"}
    {"text":"4","status":""}|{"text":"Trial and failure of, or contraindication to, both preferred and non‑preferred formulary agents OR provider submits clinical rationale supporting non‑formulary agent over all formulary agents","status":""}|{"text":"Non‑formulary DPP‑4 agent — approve up to 1 year when criteria met","status":"covered"}

    Definitions

    DPP-IV inhibitor — definition and mechanism
    ClassDipeptidyl peptidase-4 (DPP-4) inhibitors
    Mechanism of actionInhibit the dipeptidyl peptidase-4 enzyme to help control blood glucose in type 2 diabetes mellitus
    FDA‑approved indicationType 2 diabetes mellitus
    Includes combination productsPolicy applies to combination agents that contain metformin and a DPP-4 inhibitor
    Coverage contextNon-preferred formulary DPP-4 agents covered after failure of first‑line metformin and a preferred formulary DPP-4 agent; nonformulary agents covered after failure of both preferred and non-preferred formulary agents

    Background

    Dipeptidyl peptidase‑4 (DPP‑4) inhibitors are an oral antihyperglycemic drug class used for glycemic control in patients with type 2 diabetes mellitus. This policy defines prior authorization requirements for non‑preferred and non‑formulary DPP‑4 agents (including combination products containing metformin), emphasizing use after first‑line therapy with metformin and, when applicable, preferred formulary DPP‑4 agents have failed or are contraindicated.

    Prior authorization is required for non‑preferred and non‑formulary DPP‑4 inhibitors; when criteria are met, approvals may be granted for up to 1 year. Documentation submitted must demonstrate the diagnosis and relevant prior trials, failures, or contraindications, and for non‑preferred or non‑formulary agents must include a clinical rationale when required by the criteria.

    Policy Summary
    Payerallcareadvantage
    PolicyDipeptidyl peptidase-4 (DPP-4) inhibitors prior authorization
    Policy CodePolicy 024.2
    Change TypeNo material change
    Effective DateMar 28, 2025
    Last ReviewMar 28, 2027
    Next Review DateMar 28, 2027
    Key ActionObtain prior authorization and document diagnosis plus trials/failures or contraindications to metformin and preferred DPP-4 agents; approvals granted up to 1 year when criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy RequirementsRenewal / Continuation CriteriaProvider Actions and Documentation RequirementsStep Therapy RequirementsDefinitionsBackground

    Required clinical documentation and rationale

    Documentation must clearly show a diagnosis of type 2 diabetes mellitus and evidence of prior trials and failures or documented contraindications to metformin and to preferred formulary DPP-4 agents as applicable. For requests for non-preferred or non-formulary agents, a clinical rationale supporting use over preferred/formulary agents must be submitted; renewals require recent chart notes supporting continued use.

    • Diagnosis of type 2 diabetes mellitus documented in the record
    • Evidence of trial and failure or contraindication to metformin (first-line)
    • Evidence of trial and failure or contraindication to preferred formulary DPP-4 agent(s) when required
    • Clinical rationale submitted for use of non-preferred or non-formulary agent over formulary options
    • Recent chart notes supporting continued use for renewals
    Denial Risk

    Denial risks for insufficient diagnosis or prior therapy

    Requests will be denied if documentation does not support a diagnosis of type 2 diabetes mellitus or fails to demonstrate required prior trials/failures or contraindications to metformin and applicable formulary DPP-4 agents; lacking a submitted clinical rationale for non-preferred or non-formulary use also risks denial.

    • Deny if no documentation of type 2 diabetes mellitus
    • Deny if no evidence of trial/failure or contraindication to metformin when required
    • Deny if provider does not submit rationale to support non-preferred/non-formulary use over formulary agents
    Denial Risk

    Renewal denial conditions

    For renewals, denials will occur if the member did not meet the initial prior authorization criteria or if recent chart notes do not support continuation of the medication; approvals on renewal are up to 1 year when continuation is supported.

    • Renewal denied if initial PA criteria were not met
    • Renewal denied if recent chart notes do not support continued therapy
    • If renewal criteria met, approve up to 1 year